GUILDFORD, England,
June 3, 2015 /PRNewswire/
-- ANGLE plc (AIM: AGL) (OTCQX: ANPCY), the specialist medtech
company, is pleased to announce the appointment of James M. Reuben, PhD, MBA, as a Scientific
Advisor to the Company with immediate effect.
Dr Reuben is a Professor in the Department of Hematopathology,
Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center,
Houston, Texas. He has conducted
extensive research on circulating tumor cell (CTC) subsets,
including those with epithelial and mesenchymal phenotypes and
their clinical relevance to minimal residual disease in breast
cancer.
The University of Texas MD Anderson
Cancer Center is one of the world's most respected centres devoted
exclusively to cancer patient care, research, education and
prevention. A different part of MD Anderson is already
working with ANGLE as a key opinion leader in the field of
colorectal cancer.
Dr Reuben is a leader in translational medicine at MD Anderson
and in particular in the area of CTCs and liquid biopsies, a key
area of medical development in which he has been working for many
years. Translational medicine is the field involved in taking
new research and getting it applied in the treatment of
patients.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"Jim Reuben has exceptional knowledge of
circulating tumor cells. He was one of the leading
investigators in the earliest studies on CTCs and has been very
actively involved ever since. We are delighted that he has joined
ANGLE's Scientific Advisory Board and believe his in-depth
knowledge and understanding of CTCs and wide network of contacts in
the field will be of great benefit to ANGLE as we drive towards the
widespread adoption of the Parsortix system in cancer care."
For further information:
www.angleplc.com
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc
www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United
States, China and
Australia and three extensive
families of patents are being progressed worldwide. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The Parsortix system
is established with strong positive evaluations from leading cancer
research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for
Europe and FDA authorisation is in
process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE has established formal collaborations with world-class
cancer centres and is working with these cancer centres to
demonstrate key applications for its Parsortix non-invasive cancer
diagnostic system as a liquid biopsy. Details are available
here http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the
ticker symbol AGL.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/angle-plc-appoints-jim-reuben-scientific-adviser-300093218.html
SOURCE ANGLE plc
